Saturn V Capital Management LP
Long book
$552.2M
Q1 2026
Positions
21
Top-10 weight
77%
concentration
Last quarter
+18.5%
SPY +14.8%
Turnover
29%
of book per quarter
Strategy in plain words
auto-generated from filingsSaturn V Capital Management LP is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $552.2M US long book across 21 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: ALUMIS INC, AMYLYX PHARMACEUTICALS INC, ABIVAX SA-ADR, VAXCYTE INC, PHARVARIS NV.
Over the last 9 quarters its long book ran on average 8.3pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-4.2%
Q2 2024
+13.1%
Q3 2024
-15.0%
Q4 2024
-23.8%
Q1 2025
+9.6%
Q2 2025
+76.5%
Q3 2025
+32.2%
Q4 2025
+8.4%
Q1 2026
+18.5%
Sector allocation
Healthcare 100%
Long book by quarter
What does Saturn V own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| ALMS ALUMIS INC | Healthcare | 3.2M | $70.5M | 12.8% | +2.1% |
| AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 4.3M | $60.5M | 10.9% | -3.3% |
| PCVX VAXCYTE INC | Healthcare | 824.5K | $47.9M | 8.7% | +3.2% |
| PHVS PHARVARIS NV | Healthcare | 1.2M | $33.9M | 6.1% | +5.4% |
| IMMX IMMIX BIOPHARMA INC | Healthcare | 3.7M | $33.6M | 6.1% | +23.2% |
| CELC CELCUITY INC | Healthcare | 281.9K | $32.2M | 5.8% | -11.1% |
| JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 163.0K | $30.8M | 5.6% | -34.3% |
| IRON DISC MEDICINE INC | Healthcare | 449.9K | $28.8M | 5.2% | +50.8% |
| XFOR X4 PHARMACEUTICALS INC | Healthcare | 6.5M | $26.7M | 4.8% | +11.3% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 626.6K | $24.1M | 4.4% | -48.5% |
| MNPR MONOPAR THERAPEUTICS INC | Healthcare | 345.6K | $18.9M | 3.4% | +6.1% |
| DYN DYNE THERAPEUTICS INC | Healthcare | 966.6K | $17.5M | 3.2% | -46.0% |
| IVVD INVIVYD INC | Healthcare | 10.9M | $14.2M | 2.6% | +41.5% |
| CADL CANDEL THERAPEUTICS INC | Healthcare | 2.9M | $14.2M | 2.6% | New |
| OCS OCULIS HOLDING AG | Healthcare | 516.8K | $13.7M | 2.5% | Held |
| OVID OVID THERAPEUTICS INC | Healthcare | 4.2M | $9.2M | 1.7% | +66.7% |
| IKT INHIBIKASE THERAPEUTICS INC | Healthcare | 3.9M | $6.5M | 1.2% | +0.2% |
| ZURA ZURA BIO LTD | Healthcare | 740.0K | $4.4M | 0.8% | New |
| ANRO ALTO NEUROSCIENCE INC | Healthcare | 89.0K | $2.0M | 0.4% | New |
| MSLE SATELLOS BIOSCIENCE INC | Healthcare | 350.0K | $2.0M | 0.4% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 21 | $552.2M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 20 | $544.9M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 17 | $456.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 13, 2025 | 24 | $246.8M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 21 | $198.2M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 24 | $255.4M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 25 | $279.8M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 26 | $264.6M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 21 | $249.4M | canonical | SEC ↗ |